Proteins are the most versatile materials used by the cell to support biological activity. It is no surprise that so much effort is devoted not only to decoding genomes in terms of the identification and annotation of the encoded proteins, but also most importantly to understanding the functions of proteins, their regulation and their interactions in the cell. Beyond this 'scouting' stage, whose dimensions and scientific breadth cannot be underestimated, the focus is on the many different aspects of protein structure, reactivity and regulation that define their mechanisms of action. In fact, these aspects may be seen as one of the main targets of basic and applied protein science.

Proteins often display biological activities that affect the structure or function of other (macro)molecules. For example, enzymes act on substrates or recognize partners that vary widely in size and type, from electrons, to diatomic 'small' molecules, to other proteins or peptides, to DNA--protein assemblies and chromatin. But proteins are also clever carriers, signaling entities, actors in the cascades of the immune response and crucial players in redox processes. In this context, the parallel analysis of proteins within a homologous superfamily, or within a functional group, is a useful approach for obtaining mechanistic insight and also for supporting technological applications. Indeed, protein science is steadily moving towards, and supporting, applied research. The ten contributions presented in this year\'s Proteins section of *Current Opinion in Structural Biology* are grouped into the following two broad areas: proteins in basic research and biophysics; and proteins in the molecular mechanisms of disease and as drug targets.

The field of protein science has continuously gained fresh input from the development of new methods, often provided by high-level instrumentation, by large-scale facilities, and by the development of fundamental theories and their translation into algorithms, simulation methods and experimental practice. Certainly none of the papers collected in this year\'s Proteins section would have been such without the contribution of one (or more) of these advanced methods.

The birth of modern biology is considered to be the discovery of the microscope in the late seventeenth century by Anton van Leeuwenhock, which opened the way to the exploration of cellular architecture. Biological applications of optical microscopy have witnessed remarkable developments in the past decade, thanks to progress in high-sensitivity instrumentation and methods, and to the development of protein optical-imaging probes, which can be selectively targeted using molecular biology techniques. The review presented by Remington introduces the fascinating world of fluorescent proteins, which were discovered in marine jellyfish. A conserved protein fold based on an antiparallel β-barrel hosts a unique fluorescent chromophore resulting from the spontaneous reaction of neighboring core residues (Ser-Tyr-Gly, in green fluorescent protein). Whereas some natural variants of the chromophore result in different fluorescence emission spectra (from green to yellow-orange), knowledge of three-dimensional structures has supported a deeper chemical understanding of chromophore formation, and the design of new types of reporter chromophores and their application in advanced imaging techniques, such as the detection of single molecules *in vivo*. Thus, the field is moving from the early applications of the mid-1990s, which imaged individual live neurons in *C. elegans*, to mapping chemical and dynamic properties in localized compartments at the subcellular level. Research on the photochemistry and photophysics of easily manipulated fluorescent proteins is leading to the development of photoactivable probes and real-time photosensors that will increase resolution in the space and time domains relevant to cellular processes. Stay tuned for an even richer library of fluoroproteins that can be used in combination to see multiple processes simultaneously.

Flavoenzymes have stimulated the creativity of scientists for many decades, probably due to their spectroscopic properties, which often are linked to the redox or ionization state of the flavin cofactor. A recent estimate of the distribution of flavoproteins in sequenced genomes indicates that their numbers exceed expectations (1--3%). De Colibus and Mattevi report the exciting discovery of flavoenzymes that have been implicated in cellular functions previously not ascribed to any flavoprotein. Among the 'new' enzymes, LSD1 histone demethylase, a homolog of flavin-dependent amine oxidase that acts on mono- and di-methylated lysines of histone H3, has brought entirely new concepts to the field of epigenetic markers. Flavins have long been known for their ability to activate oxygen for oxidase, monooxygenase or hydroxylase reactions. New atomic-resolution structures coupled to biophysical techniques (e.g. single-crystal microspectrophotometry) have enabled detailed analysis of new mechanisms of action. A remarkable example is provided by the enzyme tryptophan 7-halogenase, in which hypochlorite, produced by the reaction of chloride with a flavin peroxide, is channeled through an intramolecular tunnel from the FAD site to the tryptophan indole ring. The overall picture is that the chemical versatility of flavin-dependent enzymes is only beginning to be discovered, with areas such as flavin electron transfer, modulation of dioxygen reactivity and multienzyme complexes remaining a massive field for innovative experimentation.

Copper bioinorganic chemistry is held to have received a boost when primitive photosynthetic organisms started to increase the O~2~ content of our atmosphere about 1.7 billion years ago. Not surprisingly, many current enzymes containing mono-, di- and tri-nuclear copper centers are involved in biological mono- and di-oxygenase reactions and substrate oxidation. Although the overall reaction scheme for many copper enzymes can be reconciled with a common sequential scheme (O~2~ coordination to a copper center, O~2~ activation, followed by oxidation of a substrate), the detailed mechanisms vary from enzyme to enzyme, and have been the subject of intense structural biology investigations in the past two years. The review by Rosenzweig and Sazinsky presents the most significant advances for the families of monocopper (type 2 copper center) enzymes, dicopper (type 3) enzymes and multicopper oxidases, in which a type 1 blue copper center coexists with type 2 and type 3 centers (known eukaryotic examples are laccase, ascorbate oxidase and ceruloplasmin). The reported crystal structures, while often displaying conserved domain folds, shed light on the different schemes adopted for tuning the reactivity of the copper centers and on the stereochemistry adopted by the activated O~2~ intermediates used in catalysis. Recent exciting results on two homologous enzymes, particulate methane monooxygenase and ammonia monooxygenase, open the door to new exciting work on integral membrane copper enzymes, in which structural features of mono- and di-nuclear copper centers are recognized together with, potentially, additional metal centers.

Nitric oxide (NO) is an important signaling molecule, and our understanding of its importance continues to grow. Soluble guanylate cyclase (sGC) is a key molecule in a well-established NO signaling pathway. NO binds the heme cofactor of the sGC heme domain, which activates the production of cyclic GMP and in turn stimulates downstream events. The common wisdom about the mechanism is that NO binding to Fe opposite a histidine ligand 'loosens' the histidine--Fe coordination bond, leading to protein structural changes that are detected in the catalytic domain. However, this mechanism is unproven and experimental tests have confounded many researchers due to difficulties in handling the sGC αβ heterodimer. No structures are available for eukaryotic sGC or for any isolated domains. Recent structures of the monomeric heme-binding domain of a bacterial homolog have at last provided a framework for the study of sGC activation (and revealed a novel fold for heme binding). These structures, all of the same protein, were obtained in three different crystal forms by two groups, who propose competing models for activation based on biochemical and spectroscopic studies. Poulos reviews the interesting controversy, which continues unabated because the crystal structures do not eliminate either model. Unanswered questions include whether both O~2~ and NO can bind the heme, and whether NO has a second non-heme binding site on the protein. Stay tuned for more model variants before this puzzle is solved.

Lateral gene transfer, or conjugation, by the translocation of DNA between adjacent bacterial cells was discovered more than 50 years ago. After the transfer of conjugative plasmids, the recipient (transconjugant) cell becomes capable of starting new rounds of conjugation, thus supporting the efficient dissemination of enabling genes, for example, antibiotic resistance, to the population. The transfer of single-stranded DNA between bacterial cells, and across membranes, can take place only through the recruitment of sophisticated protein machines, reviewed by Gomis-Rüth and Coll. Firstly, the DNA T-strand must be prepared for transfer. To this end, assembly of the relaxosome complex (containing, among other factors, an ATP-dependent relaxase/helicase and the DNA strand) is crucial. As conjugation starts when a pilus from the donor cell is anchored to the recipient cell surface, proteins with roles in pilus formation and DNA transfer through membranes are also required. The complexity of the whole conjugation process, and the involvement of multiprotein assemblies, is probably the main reason why such a crucial transfer pathway in prokaryotes, with important implications for human health and biotechnology, has remained elusive for so long. Structural biology has recently provided insight into individual components of the relaxosome and the T4SS secretion system, which is involved in the transport of DNA through membranes. Such contributions answer some of the main questions about the mechanisms and assemblies supporting conjugation, but at the same time lead to many new biochemical and structural challenges.

The control of eukaryotic DNA for critical functions such as transcription, replication, repair, mitosis, heterochromatin formation and X-chromosome silencing is regulated by a myriad of covalent modifications of specific sites within the chromatin histone core. These modifications form what has been recognized as an 'epigenetic code' that controls DNA activity, often by recruiting other proteins to specific sites in chromatin. Although the histone-modifying enzymes have been known for many years, the details of their specificities and the ability of partner proteins to alter specificities were only recently discovered. Couture and Trievel review new structures of substrate complexes of two classes of histone-modifying enzymes: acetyltransferases and methyltransferases. Histone acetyltransferases function as part of multiprotein complexes, which can alter their basal specificities. The newest structures reveal that basal specificity involves recognition of residues both upstream and downstream of the target lysine residue. The same theme exists in histone-specific lysine methyltransferases, whereby substrate recognition occurs in a SET domain. Several new structures of different SET domains bound to cognate peptides reveal the character of the binding pockets for each of three residues upstream and downstream of the target lysine. Although the new structures only scratch the surface of histone lysine acetylating and methylating enzymes, they set the stage for the study of protein complexes that modify their specificities. Stay tuned for new structures of larger, more interesting complexes.

Serpins have long been known as high molecular weight serine proteinase inhibitors displaying a peculiar inhibition mechanism. In essence, the serpin native (inhibitory active) state displays an extended loop (of about 25 residues) that targets the proteinase active site and substrate-specificity-determining region. Following docking to the proteinase, the loop is cleaved and inserted as an additional strand in the main β-sheet of the serpin, dramatically altering the overall protein structure. The inhibitory active serpin can be considered a metastable state relative to the more stable (cleaved) inactive and restructured serpin. Although more than 20 years of extensive studies on serpins have shed light on the mode of proteinase--inhibitor recognition and mechanisms of action, the complex conformational transitions that accompany the conversion of serpins to the stable cleaved species have received proper attention only more recently. Whisstock and Bottomley review the different conformational states that have been identified for serpins, showing that they can be seen as parts of a continuum folding pathway linking the inhibitory metastable state to the thermodynamic minimum achieved in the latent, restructured protein. Serpin-inactivating mutations and serpin-related diseases, resulting from the irreversible formation of polymeric aggregates and misfolding events reminiscent of those associated with Alzheimer\'s and prion diseases, are topics that are actively considered in the design of new therapeutics.

Proteases are the target of many successful drugs and continue to be a rich source of new pharmaceutical investigation. The latest progress is reviewed by Mittl and Grütter. New results are equally divided between human and pathogen proteases. New structures have been reported for protease targets from the 'A list' of the pharmaceutical industry: cancer (caspases, proteasomes, carboxypeptidase A4, PSMA), diabetes (DPP-4), cardiovascular disease (carboxypeptidases B and U), and Alzheimer\'s and other neurological disorders (BACE, carboxypeptidase A4). Most of the studies are at the early stage of searching for lead compounds that inhibit new targets, but inhibitors of DPP-4, a serine protease that inactivates glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide, are in late-stage clinical trials for the treatment of type 2 diabetes. Among the pathogen proteases are a couple of promising targets for the treatment of malaria. The malaria parasite uses cysteine and aspartyl proteases to digest erythrocyte proteins, particularly hemoglobin. The protease active sites as well as their interaction surfaces with hemoglobin are targets for the development of antimalarials. Other targets include bacterial serine proteases that digest collagen. Some pathogens produce metalloprotease toxins, such as the tetanus and botulinium neurotoxins, which cleave cell-surface SNARE proteins, and *Bacillus anthracis* lethal factor, which cleaves signaling molecules. Spurred by success with inhibitors of the hepatitis C virus protease, the cysteine protease of hepatitis A virus and the serine proteases of West Nile and dengue viruses are all under active investigation in the search for effective antiviral compounds.

Viruses are amazing in their ability to subvert the host cell machinery to viral functions while at the same time evading detection. Mesters, Tan and Hilgenfeld review recent structures of viral enzymes and show how seemingly endless are the molecular tricks employed by viruses. Much of the recent research is driven by public health concerns related to the avian influenza virus and the SARS coronavirus (CoV), and therefore centers on single-stranded RNA viruses. New structures of viral RNA-dependent RNA polymerases (RdRps) from the *Flaviviridae* and picornaviruses show how the familiar polymerase architecture is adapted by each virus for primer-independent replication. Similarly, new picornaviral and SARS CoV protease structures show some novel variations on the serine- or cysteine-based catalytic triad. New helicase structures include both monomeric (*Flaviviridae*) and hexameric (papilloma virus) examples. Recent structures also detail new enzymatic functions for viruses, including sugar metabolism and disulfide isomerization. Some progress has been reported in the development of RdRp- or protease-targeted antiviral compounds. The SARS CoV is the subject of several proteomics and structural genomics projects that aim to identify potential drug targets and determine functions for the many SARS non-structural proteins (Nsps) of unknown function. A plethora of new structures includes a potential processivity factor (Nsp7/8), single-stranded (Nsp9) and double-stranded (Nsp10) RNA-binding proteins, and poly(ADP-ribose) hydrolase (Nsp3). Other viral enzyme structures reveal new and subtle ways in which viruses block the host innate immune response. The structure of a complex of the paramyxovirus V protein shows how it obstructs interferon signaling by binding a member of the ubiquitin ligase complex, which leads to degradation of transcription factors. One of the SARS proteases removes from target proteins an interferon-induced ubiquitin-like molecule. A ubiquitin-like domain of unknown function was discovered in the structure of the protease, separate from the catalytic domain. Stay tuned for even more surprising discoveries in the short term in this intensely researched field.

Immunology is arguably the biological field in which structural biology has provided the greatest number of 'Aha!' moments or paradigm shifts. The immune response is mediated by interactions of specialized proteins with antigens or with other specialized proteins on the surface of specialized cells. Over the past 30 years, structural biology has been marching through the specialized proteins and providing an excellent understanding of how antigens, antigen peptides and specialized proteins are recognized. Rossjohn and co-workers review the current understanding of how specific T-cell receptors (TCRs) recognize specific major histocompatibility complex class I (MHC-I) proteins bound to antigen peptides (pMHC-I). A large number of TCR--pMHC-I complex structures led to a set of generalized rules for recognition. Nature, of course, follows rules only when they are convenient. The most interesting new structures explore the limits of the rules by investigating pMHC-I molecules bound to peptides that present recognition challenges for the TCR. Early progress on the next structural challenge in immunology, the CD3--TCR--pMHC-I complex, is also reviewed. This complex transmits the signal from pMHC-I binding to the TCR into the T cell through CD3, an integral membrane protein. Stay tuned for structural immunobiology to tackle membrane proteins.

Many of the reviews are snapshots of research areas in flux. Stay tuned for the next Proteins issue of *Current Opinion in Structural Biology*.

Martino\'s research interests focus on heme proteins involved in detoxification in unicellular pathogens, on viral enzymes and on co-repressor proteins that regulate transcription. He has been one of the founders of protein crystallography in Italy, a position now actively challenged, within the country, by some of his former students.

Janet\'s research has centered on the structure and function of complex enzymes in which catalytic domains work together to catalyze multistep reactions. She also has been instrumental in developing synchrotron resources for structural biologists, particularly for multiwavelength phasing.
